Targeting the androgen receptor (AR) signaling axis has been, over decades, the mainstay of prostate cancer therapy. More potent inhibitors of androgen synthesis and antiandrogens have emerged and have been successfully implemented in clinical practice. That said, the stronger inhibition of the AR signaling axis has led in recent years to an increase of prostate cancers that de-differentiate into AR-negative disease. Unfortunately, this process is intimately linked with a poor prognosis. Here, we review the molecular mechanisms that enable cancer cells to switch from an AR-positive to an AR-negative disease and efforts to prevent/revert this process and thereby maintain/restore AR-dependence
AbstractAndrogen receptor (AR) is the main target for prostate cancer therapy. Clinical approaches f...
Androgen deprivation therapy targeting the androgens/androgen receptor (AR) signaling continues to b...
Since the growth of prostate cancer is androgen-sensitive, metastatic disease has been treated by ho...
Targeting the androgen receptor (AR) signaling axis has been, over decades, the mainstay of prostate...
Around 80-90% of prostate cancer (PCa) cases are dependent on androgens at initial diagnosis; hence,...
Despite aggressive treatment for localized cancer, prostate cancer (PC) remains a leading cause of c...
The notion that androgens and androgen receptor (AR) signaling are the hallmarks of prostate cancer ...
The prostate gland is exquisitely sensitive to androgen receptor (AR) signaling. AR signaling is obl...
The conversion of androgen receptor (AR) signaling as a mechanism of growth suppression of normal pr...
Prostate cancer (PCa) remains a leading cause of cancer-related death in the USA. While localized le...
Understanding of the molecular mechanisms of prostate cancer has led to development of therapeutic s...
The androgen receptor (AR) is one of the main components in the development and progression of prost...
Prostate cancer (PCa) primarily depends on androgen receptor (AR) signaling pathway for the initiati...
The original publication is available at www.springerlink.comAlthough prostate cancer is heterogeneo...
Prostate cancer is the second most common male malignancy in the western world an increasing inciden...
AbstractAndrogen receptor (AR) is the main target for prostate cancer therapy. Clinical approaches f...
Androgen deprivation therapy targeting the androgens/androgen receptor (AR) signaling continues to b...
Since the growth of prostate cancer is androgen-sensitive, metastatic disease has been treated by ho...
Targeting the androgen receptor (AR) signaling axis has been, over decades, the mainstay of prostate...
Around 80-90% of prostate cancer (PCa) cases are dependent on androgens at initial diagnosis; hence,...
Despite aggressive treatment for localized cancer, prostate cancer (PC) remains a leading cause of c...
The notion that androgens and androgen receptor (AR) signaling are the hallmarks of prostate cancer ...
The prostate gland is exquisitely sensitive to androgen receptor (AR) signaling. AR signaling is obl...
The conversion of androgen receptor (AR) signaling as a mechanism of growth suppression of normal pr...
Prostate cancer (PCa) remains a leading cause of cancer-related death in the USA. While localized le...
Understanding of the molecular mechanisms of prostate cancer has led to development of therapeutic s...
The androgen receptor (AR) is one of the main components in the development and progression of prost...
Prostate cancer (PCa) primarily depends on androgen receptor (AR) signaling pathway for the initiati...
The original publication is available at www.springerlink.comAlthough prostate cancer is heterogeneo...
Prostate cancer is the second most common male malignancy in the western world an increasing inciden...
AbstractAndrogen receptor (AR) is the main target for prostate cancer therapy. Clinical approaches f...
Androgen deprivation therapy targeting the androgens/androgen receptor (AR) signaling continues to b...
Since the growth of prostate cancer is androgen-sensitive, metastatic disease has been treated by ho...